Dana-Farber Cancer Institute: Hodgkin Disease trials
The registry lists 13 Hodgkin Disease studies with Dana-Farber Cancer Institute as lead sponsor. 2 are open to participants now and 3 have results posted.
Phase 2 6No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialRecruitingNCT06923397Not applicable
- Establishing a Tumor Bank in Families With Multiple Lymphoproliferative MalignanciesRecruitingNCT00131014
- Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLActive, not recruitingNCT04938232Phase 2Results posted
- Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHLCompletedNCT02362997Phase 2Results posted
- Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's DiseaseCompletedNCT00601146Not applicableResults posted
- Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based ChemotherapyCompletedNCT00165438
- Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal IrradiationActive, not recruitingNCT00165425Not applicable
- Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's DiseaseCompletedNCT00165412
- Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease SurvivorsCompletedNCT00165308Not applicable
- Mantle Irradiation for Hodgkin's DiseaseCompletedNCT00165269Phase 2
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationCompletedNCT00144703Phase 2
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
- Amifostine for Head and Neck Irradiation in LymphomaCompletedNCT00136474Phase 2